What is the price of Kexing Biopharm Co., Ltd. (688136)

The price of Kexing Biopharm Co., Ltd. (688136) is $3.13

What is the market cap of Kexing Biopharm Co., Ltd. (688136)

The market cap of Kexing Biopharm Co., Ltd. (688136) is $621.33M

Kexing Biopharm Co., Ltd. (688136) P/S Ratio

Kexing Biopharm Co., Ltd. is a global pharmaceutical enterprise primarily involved in the exploration, manufacturing, and commercialization of advanced recombinant protein-based drugs and microbial preparations, serving both the Chinese domestic market and international clientele. The company strategically directs its research and development endeavors towards crucial medical areas, specifically focusing on antiviral therapies, oncology, immunology, hematological conditions, digestive system health, and degenerative diseases. Its extensive product lineup features diverse pharmaceutical solutions. This includes innovative recombinant human proteins such as interferon a1b, erythropoietin, and granulocyte stimulating factor. Additionally, their offerings encompass microbial formulations like Clostridium butyricum combined live bacteria powder, traditional Chinese patent medicines (e.g., Kehuang Capsule), and chemical drugs like Entecavir. Kexing Biopharm also provides cutting-edge biologics, including liraglutide (a human glucagon-like peptide-1), along with other specialized therapeutics such as Albumin-Paclitaxel, Infliximab, Bevacizumab, adalimumab, trastuzumab, neratinib maleate tablets, and lenalidomide capsules. Established in 1989, the company's main operations are situated in Jinan, China.

Year	P/S Ratio	Change
Not enough data for the provided dates.

Year

P/S Ratio

Change

Not enough data for the provided dates.

Company	P/S Ratio	P/S Ratio Difference	Country
Vertex Pharmaceuticals Incorporated VRTX.US	10.17	-	US
Argenx SE ARGX.US	10.13	-	NL
CSL Limited CSL.AX	2.95	-	AU
Moderna, Inc. MRNA.US	11.28	-	US
Lonza Group AG LONN.SW	-	-	CH

Company

P/S Ratio

P/S Ratio Difference

Country